Search

Your search keyword '"Baselga, Jos"' showing total 8 results
Start Over Author "Baselga, Jos"
8 results on '"Baselga, Jos"'

1. Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

Author

Zabala-Letona, Amaia, Arruabarrena-Aristorena, Amaia, Martn-Martn, Natalia, Fernandez-Ruiz, Sonia, Sutherland, James D., Clasquin, Michelle, Tomas-Cortazar, Julen, Jimenez, Jose, Torres, Ines, Quang, Phong, Ximenez-Embun, Pilar, Bago, Ruzica, Ugalde-Olano, Aitziber, Loizaga-Iriarte, Ana, Lacasa-Viscasillas, Isabel, Unda, Miguel, Torrano, Vernica, Cabrera, Diana, van Liempd, Sebastiaan M., Cendon, Ylenia, Castro, Elena, Murray, Stuart, Revandkar, Ajinkya, Alimonti, Andrea, Zhang, Yinan, Barnett, Amelia, Lein, Gina, Pirman, David, Cortazar, Ana R., Arreal, Leire, Prudkin, Ludmila, Astobiza, Ianire, Valcarcel-Jimenez, Lorea, Zuiga-Garca, Patricia, Fernandez-Dominguez, Itziar, Piva, Marco, Caro-Maldonado, Alfredo, Snchez-Mosquera, Pilar, Castillo-Martn, Mireia, Serra, Violeta, Beraza, Naiara, Gentilella, Antonio, Thomas, George, Azkargorta, Mikel, Elortza, Felix, Farrs, Rosa, Olmos, David, Efeyan, Alejo, Anguita, Juan, Muoz, Javier, Falcn-Prez, Juan M., Barrio, Rosa, Macarulla, Teresa, Mato, Jose M., Martinez-Chantar, Maria L., Cordon-Cardo, Carlos, Aransay, Ana M., Marks, Kevin, Baselga, Jos, Tabernero, Josep, Nuciforo, Paolo, Manning, Brendan D., Marjon, Katya, and Carracedo, Arkaitz

Abstract

Author(s): Amaia Zabala-Letona; Amaia Arruabarrena-Aristorena; Natalia Martn-Martn; Sonia Fernandez-Ruiz; James D. Sutherland; Michelle Clasquin; Julen Tomas-Cortazar; Jose Jimenez; Ines Torres; Phong Quang; Pilar Ximenez-Embun; Ruzica Bago; Aitziber Ugalde-Olano; Ana Loizaga-Iriarte; [...]

Published
2018
Full Text
View/download PDF

2. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Author

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, Jos, and Solit, David B.

Subjects
Genetic aspects, Health aspects, Cancer -- Genetic aspects, Phosphotransferases -- Health aspects, Gene mutation -- Health aspects
Abstract

Author(s): David M. Hyman (corresponding author) [1]; Sarina A. Piha-Paul [2]; Helen Won [1]; Jordi Rodon [3]; Cristina Saura [3]; Geoffrey I. Shapiro [4]; Dejan Juric [5]; David I. Quinn [...], Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, basket trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

Published
2018
Full Text
View/download PDF

3. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

Author

Zabala-Letona, Amaia, Arruabarrena-Aristorena, Amaia, Martn-Martn, Natalia, Fernandez-Ruiz, Sonia, Sutherland, James D., Clasquin, Michelle, Tomas-Cortazar, Julen, Jimenez, Jose, Torres, Ines, Quang, Phong, Ximenez-Embun, Pilar, Bago, Ruzica, Ugalde-Olano, Aitziber, Loizaga-Iriarte, Ana, Lacasa-Viscasillas, Isabel, Unda, Miguel, Torrano, Vernica, Cabrera, Diana, van Liempd, Sebastiaan M., Cendon, Ylenia, Castro, Elena, Murray, Stuart, Revandkar, Ajinkya, Alimonti, Andrea, Zhang, Yinan, Barnett, Amelia, Lein, Gina, Pirman, David, Cortazar, Ana R., Arreal, Leire, Prudkin, Ludmila, Astobiza, Ianire, Valcarcel-Jimenez, Lorea, Zuiga-Garca, Patricia, Fernandez-Dominguez, Itziar, Piva, Marco, Caro-Maldonado, Alfredo, Snchez-Mosquera, Pilar, Castillo-Martn, Mireia, Serra, Violeta, Beraza, Naiara, Gentilella, Antonio, Thomas, George, Azkargorta, Mikel, Elortza, Felix, Farrs, Rosa, Olmos, David, Efeyan, Alejo, Anguita, Juan, Muoz, Javier, Falcn-Prez, Juan M., Barrio, Rosa, Macarulla, Teresa, Mato, Jose M., Martinez-Chantar, Maria L., Cordon-Cardo, Carlos, Aransay, Ana M., Marks, Kevin, Baselga, Jos, Tabernero, Josep, Nuciforo, Paolo, Manning, Brendan D., Marjon, Katya, and Carracedo, Arkaitz

Subjects
Physiological aspects, Polyamines -- Physiological aspects, Prostate cancer -- Physiological aspects, S-adenosylmethionine -- Physiological aspects
Abstract

Author(s): Amaia Zabala-Letona [1, 2]; Amaia Arruabarrena-Aristorena [1]; Natalia Martn-Martn [1, 2]; Sonia Fernandez-Ruiz [1, 2]; James D. Sutherland [1]; Michelle Clasquin [3]; Julen Tomas-Cortazar [1]; Jose Jimenez [4]; Ines [...]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results